The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.
about
The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
The combination of an HDAC6 in ...... l of polycystic liver disease.
@en
The combination of an HDAC6 in ...... l of polycystic liver disease.
@nl
type
label
The combination of an HDAC6 in ...... l of polycystic liver disease.
@en
The combination of an HDAC6 in ...... l of polycystic liver disease.
@nl
prefLabel
The combination of an HDAC6 in ...... l of polycystic liver disease.
@en
The combination of an HDAC6 in ...... l of polycystic liver disease.
@nl
P2093
P2860
P50
P1476
The combination of an HDAC6 in ...... l of polycystic liver disease.
@en
P2093
Anatoliy I Masyuk
Nicholas F LaRusso
Sergio A Gradilone
Tatyana V Masyuk
P2860
P304
P356
10.1016/J.AJPATH.2017.12.016
P407
P577
2018-01-20T00:00:00Z